In a first-in-human study, oleclumab, either alone or in combination with the anti-PD-L1 monoclonal antibody durvalumab, demonstrated reductions in free CD73 and CD73 expression on peripheral T cells and tumor cells. Here, CD274 is linked to neoplasm.